First case of toxoplasmosis following small bowel transplantation and systematic review of tissue-invasive toxoplasmosis following noncardiac solid organ transplantation

被引:51
作者
Campbell, AL
Goldberg, CL
Magid, MS
Gondolesi, G
Rumbo, C
Herold, BC
机构
[1] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA
[2] Mt Sinai Sch Med, Dept Pathol, New York, NY 10029 USA
[3] Mt Sinai Sch Med, Dept Surg, New York, NY 10029 USA
关键词
toxoplasmosis; small bowel transplant; opportunistic infections; transplantation; systematic review;
D O I
10.1097/01.tp.0000188183.49025.d5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Toxoplasmosis prophylaxis is standard following heart and heart lung transplantation, when an increased risk of allograft transmitted Toxoplasma is well-recognized. In contrast, prophylaxis and routine serologic evaluation of donors and recipients for Toxoplasma in noncardiac solid organ transplantation (SOT) is not recommended. We report the first case of disseminated toxoplasmosis following small bowel transplantation, presumably transmitted via the transplanted intestine and systematically review reported cases of toxoplasmosis in noncardiac SOT recipients to determine if current guidelines should be reconsidered. Methods. Systematic MEDLINE review was performed for tissue invasive toxoplasmosis in noncardiac SOT recipients and analysis of clinical features, serologic status, and treatment regimens with respect to mortality. Results. Fifty-two cases of toxoplasmosis in noncardiac SOT recipients were identified. Flighty-six percent developed disease within 90 days of transplantation. Presentation was nonspecific and consisted of fever (77%), respiratory distress (29%), neurologic manifestations (29%), and bone marrow Suppression (26%). Multivariate analyses demonstrated that localized disease (odds ratio [OR] = 37.36, 95% CI 1.85-754.85), treatment received (OR = 1.814, 95% CI 1.193-3.480) and donor and recipient serostatus (OR = 1.39, 95% CI 1.068-1.815) were predictors of survival. High-risk recipients (donor seropositive/recipient seronegative) developed disease earlier (16 days vs. 31 days P = 0.002) and were less likely to survive (OR = 0.14, 95% CI 0.03-0.69) than standard-risk recipients. Conclusions. Toxoplasmosis is recognized following noncardiac SOT. Reduction of morbidity and mortality necessitates knowledge of donor and recipient Toxoplasma serostatus, prophylaxis, early diagnosis, and treatment, The findings support a reconsideration of pretransplantation evaluation and prophylaxis strategies in SOT recipients.
引用
收藏
页码:408 / 417
页数:10
相关论文
共 73 条
[1]   Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era [J].
Abgrall, S ;
Rabaud, C ;
Costagliola, D .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (10) :1747-1755
[2]  
Anthony C W, 1972, J Am Med Womens Assoc (1972), V27, P601
[3]   PCR for diagnosis and follow-up of two cases of disseminated toxoplasmosis after kidney grafting [J].
Aubert, D ;
Foudrinier, F ;
Villena, I ;
Pinon, JM ;
Biava, MF ;
Renoult, E .
JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (05) :1347-1347
[4]   INFECTIONS AND IMMUNIZATIONS IN ORGAN TRANSPLANT RECIPIENTS - A PREVENTIVE APPROACH [J].
AVERY, RK .
CLEVELAND CLINIC JOURNAL OF MEDICINE, 1994, 61 (05) :386-392
[5]   Successful toxoplasmosis prophylaxis after orthotopic cardiac transplantation with trimethoprim-sulfamethoxazole [J].
Baden, LR ;
Katz, JT ;
Franck, L ;
Tsang, S ;
Hall, M ;
Rubin, RH ;
Jarcho, J .
TRANSPLANTATION, 2003, 75 (03) :339-343
[6]  
BARCAN LA, 2002, TRANSPL INFECT DIS, V4, P934
[7]   Incidence and risk factors of toxoplasmosis in a cohort of human immunodeficiency virus-infected patients: 1988-1995 [J].
Belanger, P ;
Derouin, F ;
Grangeot-Keros, L ;
Meyer, L .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (03) :575-581
[8]   AN OPPORTUNITY NOT TO BE MISSED [J].
BELLI, AM ;
ELLIOTT, C ;
HERON, CW .
BRITISH JOURNAL OF RADIOLOGY, 1988, 61 (722) :171-172
[9]  
BEST T, 1979, ARCH PATHOL LAB MED, V103, P693
[10]   EFFECT OF CLINDAMYCIN ON INTRACELLULAR REPLICATION, PROTEIN-SYNTHESIS, AND INFECTIVITY OF TOXOPLASMA-GONDII [J].
BLAIS, J ;
TARDIF, C ;
CHAMBERLAND, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (12) :2571-2577